JY 208
Alternative Names: JY-208Latest Information Update: 01 Dec 2022
At a glance
- Originator Shenzhen Enduring Biotech
- Class Antineoplastics; Drug conjugates; Immunoconjugates; Immunoglobulin Fv fragments; Polyethylene glycols; Recombinant fusion proteins
- Mechanism of Action Cell death stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Solid tumours
Most Recent Events
- 23 Nov 2022 Preclinical trials in Solid tumours in China (Parenteral) prior to November 2022 (Shenzhen Enduring Biotech pipeline; November 2022)
- 20 Jul 2021 Shenzhen Enduring Biotech has patent protection for its core technology platform in USA (Shenzhen Enduring Biotech website; November 2022).
- 15 Apr 2021 Shenzhen Enduring Biotech files a PCT application for Antibody drug conjugate worldwide